Common Stock, $0.0001 par value per share
- Symbol
- NERV
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Minerva Neurosciences, Inc
NERVNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, the Board of Directors (the “Board”) of Minerva Neurosciences, Inc.…
Company context
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Current securities
Registered securities in this filing
Minerva Neurosciences, Inc. · 8-K · Filed 2026-08-12
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 10, 2026, the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) appointed Anthony Aliquo, the Company’s Vice President, Controller, as Chief Accounting Officer and principal accounting officer of the Company, effective as of that date. Effective as of the same date, Fred Ahlholm, Chief Financial Officer of the Company, ceased to serve as the Company’s principal accounting officer. Mr. Ahlholm will continue to serve as the Company’s Chief Financial Officer and principal financial officer.
Mr. Aliquo, age 39, served as Vice President, Controller for the Company from November 2022 to July 2026, as Controller from August 2021 to November 2022 and as Assistant Controller from September 2020 to August 2021. Prior to such, Mr. Aliquo served as an Auditor for BDO USA, P.C. and, before that, he served as an Auditor for Deloitte & Touche, LLP. Mr. Aliquo is a CPA with over 10 years of accounting experience. He holds a M.S. degree in Accountancy from University of North Carolina Wilmington and a B.S. degree in Mathematics from Saint Michael’s College.
In connection with Mr. Aliquo’s appointment, the Board, upon the recommendation of the Compensation Committee of the Board, approved (i) an increase in Mr. Aliquo’s annual base salary to $296,696, effective July 1, 2026, and (ii) an increase in his annual performance bonus target to 35% of Mr. Aliquo’s annual base salary. Other than the foregoing, Mr. Aliquo’s compensatory and other arrangements with the Company will continue as in effect prior to his promotion.
There are no arrangements or understandings between Mr. Aliquo and any other person pursuant to which he is being appointed as Chief Accounting Officer of the Company. Mr. Aliquo has no family relationship with any of the executive officers or directors of the Company, and he has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.